Iovance Biotherapeutics, Inc. Common Stock (IOVA) — Analysis Summary
Iovance Biotherapeutics, Inc. Common Stock (IOVA) has a market cap of $1.80B with year-over-year revenue growth of +60.6%. Net margin stands at -148.4%. The stock trades at a P/E ratio of -5.1.
Key Takeaways
- Revenue changed +60.6% year-over-year
- Net margin of -148.4%
- P/E ratio of -5.1
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, IOVA posted revenue growth of +60.6% and trades at a P/E of -5.1.
Iovance Biotherapeutics, Inc. Common Stock (IOVA)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -127.2% — severe operating losses
Net margin at -123.9% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
975
Headquarters
SAN CARLOS, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.